Volcano Corporation 3661 Valley Centre Drive Suite 200 San Diego,
CA 92130 United States - Map Phone: 800-228-4728 Fax: 858-720-0325 Website: http://www.volcanotherapeutics.com
Volcano Corporation designs, develops, manufactures, and commercializes a suite of precision guided therapy tools primarily to physicians, nurses, and technicians worldwide. The company offers consoles that are electronic systems, which process the signals received from intravascular ultrasound (IVUS) catheters and wires. Its IVUS products include single-use disposable catheters comprising digital and rotational catheters, as well as options comprising ChromaFlo stent apposition analysis that uses sequential IVUS frames to differentiate circulating blood from stationary or anchored tissue; and Virtual Histology IVUS that facilitates the visualization of atherosclerotic plaque. The company also provides fractional flow reserve products, including pressure and flow consoles, and single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaques physiological impact on blood flow and pressure. In addition, it develops and manufactures optical monitors for the telecommunication industry; laser and non-laser light sources; optical engines used in the medical optical coherence tomography imaging systems and advanced photonic components; and sub-systems used in spectroscopy and other industrial applications. The company sells its products through direct sales force and distributors, as well as through third parties supply and distribution agreements. Volcano Corporation was founded in 2000 and is headquartered in San Diego, California. Key Statistics
| |
| Volcano Corporation’s ISS Governance QuickScore as of Jun 1, 2013 is 9. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 9; Compensation: 10. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. R. Scott Huennekens ,
49 Chief Exec. Officer, Pres and Director | 1.17M | 569.00K | Mr. John T. Dahldorf ,
56 Chief Fin. Officer and Principal Accounting Officer | 518.00K | 598.00K | Mr. David M. Sheehan ,
50 Chief Operating Officer | 536.00K | 2.94M | Mr. Michel E. Lussier MS BME, MBA,
57 Pres of Clinical and Scientific Affairs | 510.00K | 0.00 | Mr. John Onopchenko ,
54 Exec. VP of Strategy, Bus. Devel. and Integration | 83.00K | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|